

PRESENTED BY:



SPONSORED BY:



CONTINUING MEDICAL EDUCATION

Stem Cell Transplant Weekly Conference - HLA-DQ Heterodimers in Hematopoietic Cell Transplantation – 56524-52416

Date: June 21, 2023

Time: 4:00 PM-5:00 PM

UH Cleveland Medical Center

*Neil Greenspan, MD, PhD
University Hospitals Cleveland Medical Center*

Educational Objectives

At the conclusion of this activity, the participant should be better able to:

- 1 Appreciate HLA-DQ alpha chains are effectively more polymorphic than HLA-DR and -DP alpha chains.
- 2 Review mismatches for G2 HLA-DQ molecules are worse than mismatches for G1 HLA-DQ molecules with respect to both risk of relapse and disease-free survival.
- 3 Comprehend that as a result of the preceding point, HLA-DQ antigenicity and antigen presentation capacity is likely more complex than is the case for HLA-DR and DP molecules.
- 4 Recognize known constraints on which HLA-DQ alpha chains can pair effectively with DQ beta chains as embodied by the G1 and G2 HLA-DQ groupings.
- 5 Identify that the presence of more g@ HLA-DQ molecules in HLA-matched recipients is associated with creased risk of relapse and decreased disease-free survival.
- 6 Distinguish that amino acid sequence variability for both chains of HLA-DQ molecules can indicate mismatches that can be identified on the basis of both cis and trans heterodimers

Accreditation and Credit Designation Statements

Case Western Reserve University School of Medicine is accredited by the Accreditation Council for Continuing Medical Education to provide continuing medical education for physicians.

Case Western Reserve University School of Medicine designates this live activity for a maximum of 1.00 *AMA PRA Category 1 Credits*[™]. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

Disclosures:

All relevant financial relationships have been mitigated. This activity’s planners and speaker(s) have made the following disclosures:

Name of individual	Individual's role in activity	Name of Ineligible Company(s) / Nature of Relationship(s)
Brenda Cooper, MD	Course Director	Nothing to disclose - 05/26/2023
Neil Greenspan, MD, PhD	Faculty	Consulting Fee-Sumitomo Dainippon

PRESENTED BY:

SPONSORED BY:



SCHOOL OF MEDICINE
CASE WESTERN RESERVE
UNIVERSITY

		Pharma Oncology (Relationship has ended) Stocks or stock options, excluding diversified mutual funds-Bristol-Myers Squibb Stocks or stock options, excluding diversified mutual funds-Merck and Company, Inc. Stocks or stock options, excluding diversified mutual funds-Organon and Co. Stocks or stock options, excluding diversified mutual funds-Procter & Gamble - 02/06/2023
Lauren Brister, MSN, APRN-CNP	Other Planning Committee Member	Nothing to disclose - 07/05/2022
Melissa Copley, PharmD	Other Planning Committee Member	Nothing to disclose - 06/05/2023
Molly Gallogly, MD, PhD	Other Planning Committee Member	Nothing to disclose - 06/23/2022
Leland Metheny, MD	Other Planning Committee Member	Speakers Bureau-Incyte Advisor-Bristol-Myers Squibb (Relationship has ended) Advisor-Gamida (Relationship has ended) - 07/12/2022
Frank Oley, PharmD	Other Planning Committee Member	Nothing to disclose - 05/04/2023
Benjamin Tomlinson, MD	Other Planning Committee Member	Consulting Fee-Chimerics Speakers Bureau-BMS - 04/18/2023